Consulting and PK/PD Modelling Services for Preclinical and Clinical Biotherapeutics Development
Mission
We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.
Services
Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection and dose / regimen finding studies.
Why choose us
Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.
Partners
LYO-X is member of the iBx Network. We provide integrated consulting in toxicology, pathology, preclinical and clinical pharmacology and regulatory strategies.
LYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.
LYO-X Kurzgesagt
Small Data Big Results
Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics
-
ECCMID 2019 in Amsterdam
April 4, 2019We will be at ECCMID 2019 with a poster contribution and as an exhibitor. The poster is on a novel cUTI mouse model and the application of PK/PD modelling to derive the required effect in the mouse model that translates to clinical response. We used historical Levofloxacin data to establish … Read More
-
EPFL Industry Day
March 17, 2019LYO-X is excited to be invited to present at the EPFL Industry Day March 20th. We are rather proud to be among this illustrious line-up of companies: We hope to see you on the Industry Pitch March 20th or to welcome you at our booth the next day.
-
LYO-X joint BEAM to Fight Antimicrobial Resistance
February 6, 2019LYO-X joint the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) alliance, a strong Network of ~ 50 European biopharmaceutical companies committed to developing innovative products to fend-off antibiotic-resistant pathogens. We have continuously expanded our support of biotech companies with PK/PD modelling and SystemsPharmacology to translate their antibiotics more effectively … Read More
-
‘In-silico Drug Development, Modelling & Simulation’ at the University of Freiburg
November 8, 2018LYO-X will give a lecture + hands on seminar on ‘In-silico Drug Development, Modelling & Simulation’ at the University of Freiburg for Pharmacy Master Students. This is together with Dr. Regenold GmbH who will be covering complementary topics on preclinical and clinical drug development . We are looking forward to … Read More